RT Conference Proceedings
T1 Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
A1 Gebhart, G.
A1 Keyaerts, M.
A1 Guiot, T.
A1 Flamen, P.
A1 Ruiz Borrego, M.
A1 Stradella, A.
A1 Bermejo De Las Heras, B.
A1 Escriva de Romani, S.
A1 Calvo-Martinez, L.
A1 Ribelles Entrena, N.
A1 Martinez, N.
A1 Albacar Miro, C. R.
A1 Colleoni, M. A.
A1 Atienza de Frutos, M.
A1 Sampayo-Cordero, M.
A1 Cortes, J.
A1 Perez Garcia, J. M.
A1 Llombart Cussac, A.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-05-05
LK http://hdl.handle.net/10668/21902
UL http://hdl.handle.net/10668/21902
LA en
DS RISalud
RD Apr 9, 2025